References
- Moertel C G, Reitmeier R J, Schutt A J, Hahn R G. Treatment of the patient with adenocarcinoma of unknown origin. Cancer 1972; 30: 1469–72
- Sporn J R, Greenberg B R. Empiric chemotherapy in patients with carcinoma of unknown primary site. Am J Med 1990; 88: 49–55
- Greenberg B R, Lawrence H J. Metastatic cancer with unknown primary. Med Clin North Am 1988; 72: 1055–65
- Altmain E, Cadman E. An analysis of 1–539 patients with cancer of unknown primary site. Cancer 1986; 57: 120–4
- Goldberg R M, Smith F P, Ueno W, Ahlgren J D, Schein P S. S-fluorouracil, Adriamycin, and mitomycins in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986; 4: 395–9
- Woods R L, Fox R M, Tattersall M HN, Levi J A, Brodic G N. Metastatic carcinoma of unknown primary site: A randomized study of two combination chemotherapy regimens. N Engl J Med 1980; 303: 87–9
- Papa M Z, Yang J C, Vetto J T, Shiloni E, Eisenthal A, Rosenberg S A. Combined erects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary turmors. Cancer Res 1988; 48: 122–9
- Wadler S, Schwartz E L, Goldman M, et al. Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–7
- Rosenberg S A, Lotze M T, Yang J C, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–85
- Schulof R, Goldberg S, Holmlund J, Mehlman T, White C, Avis F. Outpatient recombinant interleukin-2 + alpha-interferon alternating with 5-Ruorouracil/leukovorin for metastatic colorectal and breast cancer. Society for Biotherapy 1990